We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · October 26, 2020

ASTRO 2020: Neoadjuvant Temozolomide and Radiotherapy Incorporating Metformin Appears Feasible and Safe for Treating Glioblastoma

Phase II data indicates the regimen is particularly effective in patients with methylated MGMGT gene promoter

PracticeUpdate Editorial Team

 

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading